Tcg Crossover Gp Ii, Llc Purchases 12,374 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Tcg Crossover Gp Ii, Llc acquired 12,374 shares of the stock in a transaction dated Thursday, March 12th. The stock was acquired at an average price of $24.99 per share, for a total transaction of $309,226.26. Following the completion of the transaction, the insider directly owned 657,301 shares of the company’s stock, valued at approximately $16,425,951.99. This represents a 1.92% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Tcg Crossover Gp Ii, Llc also recently made the following trade(s):

• On Monday, March 16th, Tcg Crossover Gp Ii, Llc bought 1,190 shares of Surrozen stock. The shares were acquired at an average price of $24.99 per share, with a total value of $29,738.10.
• On Friday, March 13th, Tcg Crossover Gp Ii, Llc bought 35,433 shares of Surrozen stock. The shares were acquired at an average cost of $24.88 per share, for a total transaction of $881,573.04.
• On Thursday, February 12th, Tcg Crossover Gp Ii, Llc purchased 1,093 shares of Surrozen stock. The stock was acquired at an average cost of $23.86 per share, for a total transaction of $26,078.98.
• On Wednesday, February 11th, Tcg Crossover Gp Ii, Llc purchased 17,763 shares of Surrozen stock. The stock was acquired at an average price of $23.57 per share, with a total value of $418,673.91.
• On Tuesday, February 3rd, Tcg Crossover Gp Ii, Llc acquired 4,355 shares of Surrozen stock. The shares were bought at an average cost of $21.94 per share, with a total value of $95,548.70.
• On Monday, February 2nd, Tcg Crossover Gp Ii, Llc acquired 731 shares of Surrozen stock. The shares were bought at an average price of $21.38 per share, for a total transaction of $15,628.78.
• On Friday, January 30th, Tcg Crossover Gp Ii, Llc acquired 4,271 shares of Surrozen stock. The shares were bought at an average price of $21.39 per share, for a total transaction of $91,356.69.

Surrozen Stock Performance

SRZN stock opened at $25.60 on Wednesday. The company’s fifty day moving average price is $23.58 and its 200-day moving average price is $18.29. Surrozen, Inc. has a one year low of $5.90 and a one year high of $29.59. The company has a market capitalization of $219.39 million, a PE ratio of -1.15 and a beta of 0.53.

Institutional Investors Weigh In On Surrozen

Large investors have recently bought and sold shares of the business. Millennium Management LLC raised its stake in Surrozen by 557.1% during the fourth quarter. Millennium Management LLC now owns 721,266 shares of the company’s stock valued at $16,301,000 after purchasing an additional 611,497 shares in the last quarter. Stempoint Capital LP increased its holdings in shares of Surrozen by 185.1% in the 2nd quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock worth $6,138,000 after buying an additional 445,713 shares during the last quarter. Braidwell LP increased its holdings in shares of Surrozen by 235.7% in the 4th quarter. Braidwell LP now owns 470,000 shares of the company’s stock worth $10,622,000 after buying an additional 330,000 shares during the last quarter. Spruce Street Capital LP purchased a new stake in shares of Surrozen during the 4th quarter valued at about $9,764,000. Finally, 5AM Venture Management LLC raised its position in shares of Surrozen by 25.0% during the 4th quarter. 5AM Venture Management LLC now owns 387,500 shares of the company’s stock valued at $8,758,000 after buying an additional 77,500 shares in the last quarter. Institutional investors own 66.57% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on SRZN shares. Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research report on Thursday, January 22nd. Wall Street Zen upgraded Surrozen to a “sell” rating in a research report on Friday, November 28th. Finally, Cantor Fitzgerald started coverage on Surrozen in a research note on Thursday, February 19th. They set an “overweight” rating and a $40.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $36.00.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.